Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries Ltd (ADR) : Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Mylan

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 02:22pm CET

NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Traders had a big reason to celebrate Mylan on Wednesday after the drug's generic version of Teva's Copaxone was approved by the FDA. Generic competition for Teva's drug wasn't expected until at least 2018 so this was an early surprise. While shares of Mylan rose higher on the news, Teva's shares sank as investors grew concerned over the new competition.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Limited

Mylan N.V.

Teva Pharmaceutical Industries Limited's shares fell 14.56% on Wednesday with nearly 80 million shares traded. It was a gloomy day for the stock after a generic version of its MS drug Copaxone was approved by the FDA. Copaxone is Teva's blockbuster branded drug. Jefferies analyst David Steinberg wrote, "We note, the ongoing challenges to its generics business and that with FDA approval of Mylan's generic of Copaxone, earnings/cash flow are likely to [be] affected." The approval for Mylan's drug came earlier than either company had expected. There were two different doses of Mylan's version of the drug, 20 mg and 40 mg, which were approved by the FDA. The fact that the 40 mg dosage represented over 85 percent of Teva's Copaxone prescriptions in the second quarter didn't make the news yesterday any easier for Teva traders.

Access RDI's Teva Pharmaceutical Industries Limited Research Report at:

Mylan N.V.'s shares closed up 16.20% on Wednesday with nearly 37 million shares traded. The stock sprang to life after the Food & Drug Administration approved the company's generic multiple sclerosis drug, Glatiramer Acetate. The drug is a generic version of Teva Pharmaceutical's multiple sclerosis treatment Copaxone. The company said it would begin shipping Glatiramer Acetate 40 mg/mL for 3-times-a-week injection and 20 mg/mL for once-daily injection immediately. While traders celebrated the news, Wells Fargo Securities senior analyst David Maris called the breakout "a little bit exaggerated" when speaking to CNBC. According to Maris, the generic Copaxone 40 mg could contribute about $0.13 in earnings per share per quarter. He wrote in a note however that "it may be unrealistic to assume a quick share shift given the patient population and the nature of the disease. It will bear close watching whether the market converts to a new player, or like in the case of the 20 mg, Teva is able to maintain a good amount of share." Copaxone made $4 billion for Teva in 2016.

Access RDI's Mylan N.V. Research Report at:

Our Actionable Research on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Mylan N.V. (NASDAQ: MYL) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
12/16 TEVA PHARMACEUTICAL INDUSTRIES : What you're reading online
12/16 TEVA PHARMACEUTICAL INDUSTRIES : picks Beacon, brings antibody development to li..
12/15 TEVA PHARMACEUTICAL INDUSTRIES : Israel strike to stop flights at Ben Gurion air..
12/15 TEVA PHARMACEUTICAL INDUSTRIES : Announces Exclusive Launch of Generic Viread® i..
12/15 BIOTECH MOVERS : Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) And Ampio Pharm..
12/15 TEVA PHARMACEUTICAL INDUSTRIES : Israel-based Teva Pharmaceutical to lay off 14,..
12/15DJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Globes, Tel Aviv, Israel, Shiri Habib-Valdhorn ..
12/14 TEVA PHARMACEUTICAL INDUSTRIES : Histadrut calls general strike Sunday over Teva..
12/14 TEVA PHARMACEUTICAL INDUSTRIES : CEO tells Netanyahu of hostile takeover risk
More news
News from SeekingAlpha
12/16 Teva - Aggressive Cuts Provide Relief
12/15 Teva Pharmaceutical (TEVA) Announces Restructuring Plan & Additional Measures..
12/15 Does Teva Really Have $5 Billion In Debt Payments Due Next Year?
12/15 BIOTECH FORUM DAILY DIGEST : Impacts Of Tax Reform
12/15 Teva launches generic Viread in U.S.
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,33x
EV / Sales 2018 2,23x
Capitalization 18 265 M
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 1
Average target price 24,5 $
Spread / Average Target 36%
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386